Survodutide Clinical Trial Data

Survodutide

19% Weight Loss

The highest survodutide dose (6.0 mg) produced approximately 19% body weight reduction at 46 weeks in the phase 2 obesity trial, with 40% of participants in the two highest dose groups losing at least 20%.

Le Roux et al., Lancet Diabetes and Endocrinology, 2024

Le Roux et al., Lancet Diabetes and Endocrinology, 2024

View as image

Survodutide (BI 456906) is a dual agonist of the glucagon receptor and the GLP-1 receptor, developed by Boehringer Ingelheim. Unlike tirzepatide, which pairs GLP-1 with GIP receptor agonism, survodutide pairs GLP-1 with glucagon receptor agonism. That distinction matters because glucagon increases hepatic lipid oxidation and energy expenditure, mechanisms that may be particularly relevant for patients with obesity complicated by liver fat accumulation (MASH, formerly NASH). Phase 2 data published in the Lancet Diabetes and Endocrinology and the New England Journal of Medicine showed both competitive weight loss and striking liver histology improvements, earning FDA Breakthrough Therapy, Fast Track, and EMA PRIME designations. For the broader survodutide profile, see Survodutide: The GLP-1/Glucagon Agonist Targeting Your Liver.

Phase 2 obesity trial

Le Roux et al. (2024) published the pivotal phase 2 obesity study in the Lancet Diabetes and Endocrinology. This was a randomized, double-blind, placebo-controlled, dose-finding trial that enrolled 387 adults with BMI of 27 or greater (with at least one weight-related comorbidity) or BMI of 30 or greater.^[1]

Participants were randomized to one of six survodutide dose groups (0.6, 2.4, 3.6, 4.8, or 6.0 mg weekly, with or without dose escalation) or placebo. Treatment duration was 46 weeks, with a 20-week safety follow-up.

Weight loss results by dose

The weight loss was dose-dependent and substantial:

• Placebo: approximately 2% body weight reduction
• 0.6 mg: approximately 6% reduction
• 2.4 mg: approximately 12% reduction
• 3.6 mg: approximately 13% reduction
• 4.8 mg: approximately 15% reduction
• 6.0 mg: approximately 19% reduction

Among participants in the 4.8 mg and 6.0 mg groups, approximately 40% achieved at least 20% body weight reduction, a threshold associated with resolution of many obesity-related comorbidities.

Le Roux et al. (2025) subsequently published a subgroup analysis by sex and baseline BMI, finding that weight loss was consistent across men and women, and across baseline BMI categories, though participants with higher baseline BMI tended to lose more absolute weight.^[2]

Side effects

Gastrointestinal adverse events were the most common, consistent with other GLP-1-based therapies:

• Nausea: 30-50% across dose groups (most common in early weeks, declining over time)
• Diarrhea: 15-25%
• Vomiting: 10-20%
• Decreased appetite: reported but not quantified as an adverse event in all analyses

Discontinuation rates due to adverse events were higher at the 6.0 mg dose, suggesting that the maximum tolerated dose for many patients may fall between 4.8 and 6.0 mg. Dose escalation over 16-20 weeks improved tolerability compared to rapid dose titration.

Phase 2 MASH trial

Sanyal et al. (2024) published the phase 2 MASH (metabolic dysfunction-associated steatohepatitis) trial in the New England Journal of Medicine. This was a randomized, placebo-controlled trial in 293 adults with biopsy-confirmed MASH and stage F1-F3 fibrosis.^[3]

Liver histology results

At 48 weeks, the primary endpoint (improvement in MASH without worsening of fibrosis) was met across all survodutide dose groups:

• Placebo: 14% achieved MASH resolution
• 2.4 mg: 47% achieved MASH resolution
• 4.8 mg: 62% achieved MASH resolution
• 6.0 mg: 43% achieved MASH resolution (numerically lower than 4.8 mg, possibly due to higher dropout)

For the secondary endpoint of fibrosis improvement by at least one stage without worsening of MASH:

• Placebo: 22%
• Survodutide groups: 34-43% across doses

Kaya et al. (2024) analyzed the MASH data in detail, arguing that survodutide bridges the gap between hepatic and systemic metabolic dysfunction by simultaneously addressing liver fat (via glucagon-mediated lipid oxidation) and insulin resistance (via GLP-1-mediated glucose control).^[4]

These MASH results were competitive with resmetirom (the first FDA-approved MASH drug, a thyroid hormone receptor beta agonist) and superior to what GLP-1-only agonists have shown in liver histology endpoints. The glucagon receptor component appears to be the differentiator: glucagon directly stimulates hepatic fatty acid oxidation, the process of burning liver fat for energy. For why survodutide focuses on liver fat, see Survodutide and MASH: Why This Drug Focuses on Liver Fat.

Type 2 diabetes data

Bluher et al. (2024) reported dose-response effects of survodutide on HbA1c and body weight in a dedicated type 2 diabetes population. Survodutide produced dose-dependent reductions in both endpoints, with the highest doses achieving HbA1c reductions comparable to semaglutide (approximately 1.5-2.0 percentage points from baseline). Body weight reductions in the diabetes population were approximately 2-3 percentage points less than in the non-diabetic obesity population at equivalent doses, a pattern seen across GLP-1-based therapies.^[5]

Wan et al. (2024) further analyzed weight loss data by subgroups, confirming that survodutide's efficacy was maintained across age groups, sex, and diabetes duration, with no significant treatment-by-subgroup interactions.^[6]

Lawitz et al. (2024) published efficacy, tolerability, and pharmacokinetic data showing that survodutide's dual mechanism produces measurable increases in resting energy expenditure (REE), consistent with glucagon receptor activation. This energy expenditure increase distinguishes survodutide from pure GLP-1 agonists, which reduce weight primarily through appetite suppression without increasing energy expenditure.^[7]

Pharmacological profile

Thomas et al. (2024) published biomarker and pharmacological profiling data confirming dual receptor engagement. Blood-based markers showed:

• GLP-1 pathway activation: reduced appetite scores, delayed gastric emptying
• Glucagon pathway activation: increased plasma amino acid catabolism markers, increased resting energy expenditure, reduced liver fat content (measured by MRI-PDFF)

The pharmacokinetic profile supports once-weekly injection, with a half-life of approximately 6 days. Survodutide has approximately 8 nM EC50 for the human glucagon receptor and 1 nM EC50 for the GLP-1 receptor, indicating greater potency at GLP-1R but meaningful glucagon receptor engagement at therapeutic doses.^[8]

Xiao et al. (2025) conducted an independent efficacy and safety analysis of survodutide on glycemic control and weight loss in adults with type 2 diabetes, confirming the dose-dependent metabolic benefits seen in the manufacturer-sponsored trials.^[9]

Phase 3: the SYNCHRONIZE program

Three phase 3 trials are ongoing:

SYNCHRONIZE-1 (NCT06056024): survodutide vs placebo for obesity in adults without type 2 diabetes. Le Roux et al. (2026) published baseline characteristics: approximately 1,600 participants randomized, mean BMI approximately 38 kg/m2, multiple survodutide doses tested.^[10]

SYNCHRONIZE-2 (NCT06056037): survodutide vs placebo for obesity in adults with type 2 diabetes. Wharton et al. (2026) published baseline characteristics: approximately 1,000 participants randomized, mean BMI approximately 36 kg/m2, mean HbA1c approximately 8.0%.^[11]

MASH phase 3 (specific trial identifier to be confirmed): survodutide for biopsy-confirmed MASH with fibrosis, building on the NEJM phase 2 data.

Primary results from SYNCHRONIZE-1 and -2 are expected in late 2026. If positive, regulatory filing could follow in 2027.

Dutta et al. (2025) conducted a systematic review of available survodutide efficacy and safety data, concluding that the dual GLP-1/glucagon mechanism provides a differentiated profile from existing GLP-1 agonists, particularly for patients with concurrent obesity and liver disease.^[12]

Arun et al. (2025) reviewed survodutide as a dual agonist reshaping cardiometabolic care, noting its potential position in the treatment landscape alongside semaglutide, tirzepatide, and retatrutide.^[13]

How survodutide compares

Survodutide occupies a specific niche in the multi-agonist landscape:

The glucagon receptor component gives survodutide a potential advantage over semaglutide and tirzepatide for liver-focused indications. Whether this translates to superior overall weight loss outcomes compared to tirzepatide will depend on the phase 3 data.

For a detailed comparison, see How Survodutide Differs from Other Dual Agonists. For the triple agonist comparison, see Retatrutide vs Tirzepatide vs Semaglutide: How the Triple Stacks Up.

Combination potential

Augustin et al. (2025) studied a novel NPY2R agonist (BI 1820237) in combination with survodutide, finding synergistic anti-obesity efficacy in preclinical models. The NPY2R pathway promotes satiety through a mechanism independent of GLP-1 signaling, and the combination produced greater weight loss than either agent alone.^[14]

This combination approach suggests that even if survodutide's phase 3 monotherapy results are competitive with but not superior to tirzepatide, it may find a role as a combination partner where its glucagon-mediated liver and energy expenditure effects complement other mechanisms. Awad et al. (2025) noted in their systematic review that survodutide's differentiated mechanism creates combination opportunities that pure GLP-1 agonists cannot offer.^[15]

The Bottom Line

Survodutide's phase 2 data established it as a competitive dual agonist: approximately 19% weight loss in obesity (Lancet Diabetes and Endocrinology, 2024), 62% MASH resolution at the highest dose (NEJM, 2024), and dose-dependent HbA1c reductions in type 2 diabetes. The glucagon receptor component differentiates it from tirzepatide by increasing energy expenditure and directly promoting hepatic fat oxidation. Three phase 3 trials (SYNCHRONIZE program) are ongoing with results expected in late 2026. The FDA has granted Breakthrough Therapy, Fast Track, and EMA PRIME designations based on the liver data. Whether survodutide earns its own place in the metabolic drug landscape will depend on whether the phase 3 results confirm the phase 2 promise.

Frequently Asked Questions

How much weight loss does survodutide cause?

In the phase 2 obesity trial, survodutide at the 6.0 mg dose produced approximately 19% body weight reduction over 46 weeks. At 4.8 mg, weight loss was approximately 15%. About 40% of participants in the highest dose groups lost at least 20% of their body weight. Phase 3 trial results, expected in late 2026, will provide more definitive efficacy data in larger populations.

What is survodutide and how does it work?

Survodutide (BI 456906) is a synthetic peptide that activates both the GLP-1 receptor and the glucagon receptor. It is derived from the natural gut hormone oxyntomodulin. The GLP-1 component suppresses appetite and improves glucose control. The glucagon component increases energy expenditure and promotes hepatic fat oxidation. This dual mechanism differentiates it from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP).

Does survodutide help fatty liver disease?

Phase 2 data published in the New England Journal of Medicine (Sanyal et al., 2024) showed that survodutide achieved MASH resolution without worsening of fibrosis in 47-62% of treated patients versus 14% with placebo at 48 weeks. Fibrosis improvement was observed in 34-43% of treated patients. These results earned FDA Breakthrough Therapy designation, and a phase 3 MASH trial is underway.

Is survodutide FDA approved?

No. As of March 2026, survodutide is not FDA approved. It is in phase 3 clinical trials (the SYNCHRONIZE program) for obesity with and without type 2 diabetes, plus a phase 3 trial for MASH. Phase 3 results are expected in late 2026. If positive, regulatory filing could follow in 2027. The FDA has granted Breakthrough Therapy and Fast Track designations based on phase 2 liver data.

How does survodutide compare to tirzepatide?

Both are dual agonists, but they target different receptor pairs. Tirzepatide activates GLP-1 and GIP receptors; survodutide activates GLP-1 and glucagon receptors. In phase 2 trials, tirzepatide produced slightly greater weight loss (up to 22.5%) than survodutide (up to 19%), but survodutide showed stronger MASH/liver fat data. Survodutide uniquely increases resting energy expenditure through its glucagon component, while tirzepatide's GIP component may enhance insulin secretion and fat tissue remodeling.

What are the side effects of survodutide?

The most common side effects are gastrointestinal: nausea (30-50%), diarrhea (15-25%), and vomiting (10-20%). These are consistent with other GLP-1-based therapies and typically decrease over time with continued treatment. Dose escalation over 16-20 weeks improves tolerability. Discontinuation due to adverse events was higher at the 6.0 mg dose, suggesting the maximum tolerated dose for many patients falls between 4.8 and 6.0 mg.